IFNAR1 and neoplasm: Consistent with this, IFNAR1 must be expressed by hematopoietic cells (including DCs) but not cancer cells to drive anti-tumor responses elicited by RT [37], establishing a pivotal role of the cGAS–STING–IFN-I–IFNAR1 axis in DCs in dictating therapeutic effects of RT.